The ARL2BP Knockout Jurkat Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal population of Jurkat T lymphoblasts harboring targeted disruption of the human ARL2BP gene. This loss-of-function model enables investigation of ARL2BP functions in a heterogeneous cell pool, eliminating the need for clonal isolation. The polyclonal nature supports population-level assays and minimizes clone-specific artifacts.
The Jurkat cell line is a human T-lymphocyte model derived from a pediatric T-cell leukemia patient. These suspension cells are widely used to study T-cell receptor signaling, apoptosis, and immune activation pathways, offering a robust and transfectable host for gene knockout experiments.
ARL2BP acts as a selective effector of GTP-bound ARL2, localizing to mitochondria and regulating mitochondrial morphology through interactions with fusion proteins MFN1, MFN2, and OPA1. It also associates with tubulin folding cofactors TBCD and TBCE, linking ARL2 signaling to microtubule dynamics. In addition, ARL2BP participates in ciliary transport, and loss-of-function mutations are linked to retinitis pigmentosa and Usher syndrome. Knockout of ARL2BP in this model disrupts the ARL2-ARL2BP-TBCD/TBCE axis, leading to mitochondrial network abnormalities and potential defects in microtubule-dependent processes.
In Jurkat T cells, ARL2BP disruption provides a tool to dissect mitochondrial contributions to T-cell activation and apoptosis. Mitochondrial dynamics are crucial for energy metabolism, calcium homeostasis, and cell death; therefore, ARL2BP knockout may reveal vulnerabilities in leukemia cell survival or drug resistance. This polyclonal model allows correlation of ARL2BP deficiency with altered signaling downstream of the T-cell receptor and other apoptosis regulators, within a well-characterized lymphoid background.
Applications include immunoblotting for ARL2BP and mitochondrial markers, immunofluorescence for mitochondrial morphology, flow cytometry to assess mitochondrial membrane potential and apoptosis, and co-immunoprecipitation of ARL2-ARL2BP complexes. The cells are suitable for functional genomics screens or drug testing focused on mitochondrial pathways in T-cell leukemia. For further information or custom projects, contact Ascent Research.
